List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4345637/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study. Clinical Rheumatology, 2022, 41, 641-647.	2.2	6
2	Novel biomarker for pulmonary vascular disease in systemic sclerosis patients. Clinical and Experimental Rheumatology, 2022, , .	0.8	2
3	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. Autoimmunity Reviews, 2021, 20, 102738.	5.8	38
4	Dissecting the clinical heterogeneity of adult-onset Still's disease: results from a multi-dimensional characterization and stratification. Rheumatology, 2021, 60, 4844-4849.	1.9	23
5	Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?. Autoimmunity Reviews, 2021, 20, 102750.	5.8	36
6	Why Do We Still Lack a COVID-19 Vaccine? Searching for the Missing Pieces. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, 567-568.	1.2	0
7	HLA Allele Prevalence in Disease-Modifying Antirheumatic Drugs-Responsive Enthesitis and/or Arthritis Not Fulfilling ASAS Criteria: Comparison with Psoriatic and Undifferentiated Spondyloarthritis. Journal of Clinical Medicine, 2021, 10, 3006.	2.4	1
8	Chronic-Relapsing cutaneous leukocytoclastic vasculitis in a young patient with reduced EBV-specific T cell response using enzyme-linked immunospot (ELISPOT) assay successfully treated with Valaciclovir. IDCases, 2021, 26, e01331.	0.9	0
9	Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life―cohort. Rheumatology International, 2020, 40, 107-113.	3.0	20
10	Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case–control study. Clinical and Experimental Medicine, 2020, 20, 31-37.	3.6	4
11	SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment. International Journal of Molecular Sciences, 2020, 21, 3377.	4.1	61
12	Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity—characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients. Arthritis Research and Therapy, 2020, 22, 151.	3.5	38
13	Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. Autoimmunity Reviews, 2020, 19, 102509.	5.8	13
14	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of theÂmulticentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort. PLoS ONE, 2020, 15, e0235326.	2.5	31
15	SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?. Autoimmunity Reviews, 2020, 19, 102559.	5.8	24
16	Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. Arthritis Research and Therapy, 2019, 21, 204.	3.5	40
17	CD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope Spreading. International Journal of Molecular Sciences, 2019, 20, 1920.	4.1	8
18	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. Autoimmunity Reviews. 2019, 18, 93-106.	5.8	101

#	Article	IF	CITATIONS
19	Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort. Journal of Rheumatology, 2018, 45, 864-872.	2.0	70
20	Oxidized low density lipoproteins: The bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders. Autoimmunity Reviews, 2018, 17, 366-375.	5.8	66
21	Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association. PLoS ONE, 2018, 13, e0210023.	2.5	5
22	Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: putative implication of a low anti-carbamylated protein antibodies prevalence. Open Access Rheumatology: Research and Reviews, 2018, Volume 10, 129-134.	1.6	1
23	CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases. Clinical Reviews in Allergy and Immunology, 2017, 52, 217-233.	6.5	6
24	Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis. Medicine (United States), 2017, 96, e8180.	1.0	21
25	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides,) Tj ETQq1 1 0.78	4314 rgB⊺ 5.8	Г /Overlock 107
26	Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease. Medicine (United States), 2016, 95, e3931.	1.0	13
27	Vasculitides: Proposal for an integrated nomenclature. Autoimmunity Reviews, 2016, 15, 167-173.	5.8	13
28	Antiphospholipids Syndrome Complicated by a Systemic Capillary Leak-Like Syndrome Treated With Steroids and Intravenous Immunoglobulins. Medicine (United States), 2016, 95, e2648.	1.0	10
29	Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin. Autoimmunity Reviews, 2016, 15, 102-109.	5.8	18
30	Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis. Clinical and Experimental Immunology, 2015, 181, 100-109.	2.6	13
31	AB0695â€Subspecificities of Anti-Centromeric-Associated Protein a (CENP-A) Antibodies (AB) Can Identified a Subset of Patients at Higher Risk of Developing Pulmonary Hypertension. Annals of the Rheumatic Diseases, 2015, 74, 1130.2-1130.	0.9	1
32	Raynaud's phenomenon: From molecular pathogenesis to therapy. Autoimmunity Reviews, 2014, 13, 655-667.	5.8	104
33	AB0196â€Expression of the Transcription Factor Forkhead Box E3 (FOXE3) in Monocytes from Patients with Systemic Sclerosis and Correlation with their Serological Profile. Annals of the Rheumatic Diseases, 2014, 73, 868.2-868.	0.9	2
34	Severe pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: a case report and review of the literature. Clinical and Experimental Rheumatology, 2014, 32, 267-74.	0.8	18
35	MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells. Journal of the National Cancer Institute, 2013, 105, 1172-1187.	6.3	457
36	Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis. Arthritis Research and Therapy, 2013, 15, R72.	3.5	7

FEDERICO PEROSA

#	Article	IF	CITATIONS
37	Autoantibodies Recognizing the Amino Terminal 1-17 Segment of CENP-A Display Unique Specificities in Systemic Sclerosis. PLoS ONE, 2013, 8, e61453.	2.5	10

³⁸ Effects of adjuvants for human use in systemic lupus erythematosus (SLE)-prone (New Zealand) Tj ETQq0 0 0 rgBT (Overlock 10 Tf 50 70

39	Antibody Vh Repertoire Differences between Resolving and Chronically Evolving Hepatitis C Virus Infections. PLoS ONE, 2011, 6, e25606.	2.5	31
40	Autoantibodies to intracellular antigens: Generation and pathogenetic role. Autoimmunity Reviews, 2011, 10, 503-508.	5.8	66
41	Extra-articular manifestations of rheumatoid arthritis: An update. Autoimmunity Reviews, 2011, 11, 123-131.	5.8	151
42	Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. Blood, 2010, 115, 1185-1193.	1.4	66
43	The immunodominant epitope of centromere-associated protein A displays homology with the transcription factor forkhead box E3 (FOXE3). Clinical Immunology, 2010, 137, 60-73.	3.2	10
44	CD20â€depleting therapy in autoimmune diseases: from basic research to the clinic. Journal of Internal Medicine, 2010, 267, 260-277.	6.0	78
45	Two Structurally Different Rituximab-Specific CD20 Mimotope Peptides Reveal That Rituximab Recognizes Two Different CD20-Associated Epitopes. Journal of Immunology, 2009, 182, 416-423.	0.8	27
46	Staging multiple myeloma patients with active disease using serum levels of β2m-free HLA class I heavy chain together with IgM or platelet countâ~†. Blood Cells, Molecules, and Diseases, 2009, 42, 71-76.	1.4	8
47	Soluble CD4 antigen reactivity in intravenous immunoglobulin preparations: is it specific?. Clinical and Experimental Immunology, 2008, 99, 16-20.	2.6	10
48	Rheumatic disorders as paraneoplastic syndromes. Autoimmunity Reviews, 2008, 7, 352-358.	5.8	129
49	Identification of an Antigenic and Immunogenic Motif Expressed by Two 7-Mer Rituximab-Specific Cyclic Peptide Mimotopes: Implication for Peptide-Based Active Immunotherapy. Journal of Immunology, 2007, 179, 7967-7974.	0.8	23
50	New therapies in multiple myeloma. Clinical and Experimental Medicine, 2007, 7, 83-97.	3.6	37
51	Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood, 2006, 107, 1070-1077.	1.4	87
52	CD20 Mimicry by a mAb Rituximab-Specific Linear Peptide: A Potential Tool for Active Immunotherapy of Autoimmune Diseases. Annals of the New York Academy of Sciences, 2005, 1051, 672-683.	3.8	15
53	CD20: A target antigen for immunotherapy of autoimmune diseases. Autoimmunity Reviews, 2005, 4, 526-531.	5.8	71
54	Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease. Clinical and Experimental Medicine, 2005, 5, 141-160.	3.6	13

#	Article	IF	CITATIONS
55	Human CD4 mimicry by anti-idiotypic monoclonal antibody 16D7 is based on a conformational epitope. Immunology Letters, 2004, 95, 145-153.	2.5	3
56	Size variants of beta-2-microglobulin-free human leucocyte antigen class I heavy chain make different contributions to its serum increase in multiple myeloma. British Journal of Haematology, 2003, 120, 36-43.	2.5	4
57	β2-Microglobulin-Free HLA Class I Heavy Chain Epitope Mimicry by Monoclonal Antibody HC-10-Specific Peptide. Journal of Immunology, 2003, 171, 1918-1926.	0.8	150
58	Beta-2 microglobulin-free HLA class I heavy chain (FHC) A3 and/or A30 soluble products contribute only minimally to serum FHC expression. International Journal of Immunogenetics, 2002, 29, 409-412.	1.2	2
59	Assessment of safety and the immune response to the CD4 "internal antigen" mouse anti-idiotypic Mab 16D7 in four patients with SLE. Journal of Clinical Immunology, 2002, 22, 13-22.	3.8	5
60	Human CD4 internal antigen anti-idiotypic monoclonal antibody. Immunochemical and sequence analysis. Clinical and Experimental Medicine, 2001, 1, 81-89.	3.6	2
61	Increased serum levels of β2mâ€free HLA class I heavy chain in multiple myeloma. British Journal of Haematology, 1999, 106, 987-994.	2.5	14
62	Serum levels of beta-2-microglobulin-free heavy chain of HLA class I antigen in healthy individuals: relationship to their class I allotype. Human Immunology, 1999, 60, 1058-1066.	2.4	8
63	Evaluation of biotinylated cells as a source of antigens for characterization of their molecular profile. International Journal of Clinical and Laboratory Research, 1998, 28, 246-251.	1.0	3
64	The Fab region of IgG2 human myeloma proteins does not bear the streptococcal protein G-specific determinant. Journal of Immunological Methods, 1997, 203, 153-155.	1.4	7
65	Absence of streptococcal protein G (PG)-specific determinant in the Fab region of human IgG2. Clinical and Experimental Immunology, 1997, 109, 272-278.	2.6	4
66	Anti-Idiotypic Monoclonal Antibody (mAb) to Anti-CD4 mAb as Surrogate of Human CD4 Antigen (Ag) for Active Immunotherapy of Autoimmune Diseases. , 1997, , 239-254.		0
67	Anti-CD4 monoclonal antibody (mAb) and anti-idiotypic mAb to anti-CD4 in the therapy of autoimmune diseases. Clinical and Experimental Rheumatology, 1997, 15, 201-10.	0.8	5
68	Cloning and chromosomal localization of a cDNA encoding a mitochondrial porin fromDrosophila melanogaster. FEBS Letters, 1996, 384, 9-13.	2.8	25
69	Human CD4-internal antigen anti-idiotypic monoclonal antibody: induction of a CD4-specific response in humans. Journal of Immunology, 1996, 156, 3563-9.	0.8	6
70	Human CD4 "internal antigen―mimicry by anti-idiotypic monoclonal antibodies. International Journal of Clinical and Laboratory Research, 1994, 24, 33-40.	1.0	9
71	Anti-idiotypic monoclonal antibodies (mAb) to an anti-CD4 mAb induce CD4+ T cell depletion in rabbit. International Journal of Clinical and Laboratory Research, 1994, 24, 208-212.	1.0	4
72	Soluble CD4 and commercial immunoglobulin. Lancet, The, 1994, 343, 1638.	13.7	0

#	Article	IF	CITATIONS
73	Immunochemical and functional characterization of anti-idiotypic antibodies to a mouse anti-CD4 monoclonal antibody. International Journal of Clinical and Laboratory Research, 1992, 21, 179-185.	1.0	3
74	Anti-idiotypic monoclonal antibodies reacting with idiotope on isolated-denatured chains of an anti-CD4 monoclonal antibody. Immunology, 1991, 74, 748-50.	4.4	13
75	Purification of human immunoglobulins by sequential precipitation with caprylic acid and ammonium sulphate. Journal of Immunological Methods, 1990, 128, 9-16.	1.4	107
76	Purification of Murine IgG Monoclonal Antibodies by Precipitation with Caprylic Acid: Comparison with Other Methods of Purification. Hybridoma, 1989, 8, 85-95.	0.6	109
77	[5] Serological methods to detect anti-idiotypic antibodies. Methods in Enzymology, 1989, 178, 74-90.	1.0	17
78	Murine antiidiotypic monoclonal antibodies that bear the internal image of HLA-DR allospecificities Journal of Clinical Investigation, 1989, 84, 907-914.	8.2	15
79	Syngeneic antiidiotypic monoclonal antibodies to the murine anti-HLA-DR,DP monoclonal antibody CR11-462. Human Immunology, 1988, 23, 255-269.	2.4	16
80	Syngeneic anti-idiotypic antisera to murine anti-HLA class II monoclonal antibodies. Journal of Immunology, 1987, 139, 1232-9.	0.8	9
81	A sandwich assay to detect and characterize syngeneic anti-idiotypic antibodies to murine anti-HLA and tumor associated antigen monoclonal antibodies. Journal of Immunological Methods, 1986, 95, 47-55.	1.4	15
82	Human immunoglobulins in therapy. Rationale and clinical applications. Research in Clinic and Laboratory, 1983, 13, 183-202.	0.3	1